Polaryx Therapeutics (PLYX) Total Liabilities (2024 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Total Liabilities of $1.0 million for Q1 2026, up 67.6% quarter-over-quarter from $605000.0 in Q4 2025.

Polaryx Therapeutics (PLYX) Total Liabilities (2024 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Total Liabilities for 3 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Total Liabilities changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $605000.0, up 109.34% from the prior year.
Total Liabilities advanced to $1.0 million in Q1 2026 per PLYX's latest filing, from $605000.0 in the prior quarter.
Across five years, Total Liabilities topped out at $1.0 million in Q1 2026 and bottomed at $289000.0 in Q4 2024.
Historically, Total Liabilities has averaged $636000.0 across 3 years, with a median of $605000.0 in 2025.
On a YoY basis, Total Liabilities climbed as much as 109.34% in 2025 and fell as far as 109.34% in 2025.
Polaryx Therapeutics' Total Liabilities stood at $289000.0 in 2024, then surged by 109.34% to $605000.0 in 2025, then surged by 67.6% to $1.0 million in 2026.
Business Quant data shows PLYX's Total Liabilities at $1.0 million in Q1 2026, $605000.0 in Q4 2025, and $289000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	7.18 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	10.02 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.62 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	4.20 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	4.00 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.20 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.35 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	10.03 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	3.22 Bn
10	Polaryx Therapeutics	102.35 Mn	90.81 Mn	-	873,000.00

Download Data